GlobalData on MSN

Moderna scraps mRNA vaccine in congenital CMV on Phase III failure

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients will continue.

Moderna CMV Vaccine Development Halted After Missing Trial Endpoint

Moderna said its cytomegalovirus (CMV) vaccine didn't meet the primary efficacy endpoint in a Phase 3 trial, and it is discontinuing the clinical development program.

Moderna (MRNA) Is Down 9.6% After Cutting 2025 Sales Outlook and Ending CMV Vaccine Program – Has Sentiment Shifted?

In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the previous year, alongside a net loss of US$200 million and lowered full-year ...
Clinical Trials Arena on MSN

Kamada enrols first subject in Cytogam trial for CMV infection

The controlled multi-centre, randomised, prospective trial is investigating the therapy in kidney transplant recipients.
Stocktwits on MSN

Moderna Stock Slides After-Hours On CMV Vaccine Failure In Phase 3 Trial — Retail Traders Warn Of ‘Endless’ Cash Burn

Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a large Phase 3 trial, prompting the company to end its congenital CMV program.
Infectious Disease Advisor

Moderna’s CMV Vaccine Candidate Misses in Late Stage Trial

Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.

Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation

The study, titled “ Strategic Help with Immunoglobulin to Enhance protection against Late Disease (CMV) ” or SHIELD, is a prospective, randomized, controlled multicenter investigator-initiated study ...